CA2995380A1 - (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer - Google Patents
(s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer Download PDFInfo
- Publication number
- CA2995380A1 CA2995380A1 CA2995380A CA2995380A CA2995380A1 CA 2995380 A1 CA2995380 A1 CA 2995380A1 CA 2995380 A CA2995380 A CA 2995380A CA 2995380 A CA2995380 A CA 2995380A CA 2995380 A1 CA2995380 A1 CA 2995380A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- compound
- disease
- wound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562206472P | 2015-08-18 | 2015-08-18 | |
| US62/206,472 | 2015-08-18 | ||
| PCT/US2016/047566 WO2017031323A1 (en) | 2015-08-18 | 2016-08-18 | (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2995380A1 true CA2995380A1 (en) | 2017-02-23 |
Family
ID=56799634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2995380A Abandoned CA2995380A1 (en) | 2015-08-18 | 2016-08-18 | (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10363247B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3337797A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018528196A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108137563A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016308829A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2995380A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201890524A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1255438A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL257422A (cg-RX-API-DMAC7.html) |
| MA (1) | MA42655A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018001979A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017031323A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6397010B2 (ja) | 2013-07-03 | 2018-09-26 | カリオファーム セラピューティクス,インコーポレイテッド | 置換されたベンゾフラニル及びベンゾオキサゾリル化合物並びにその使用 |
| WO2015042414A1 (en) | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
| WO2017031323A1 (en) | 2015-08-18 | 2017-02-23 | Karyopharm Therapeutics Inc. | (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer |
| US10858347B2 (en) | 2015-12-31 | 2020-12-08 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
| CN111171233B (zh) * | 2020-01-17 | 2023-03-31 | 吉林师范大学 | 一种新型磁性薄层印迹膜的制备方法及用途 |
| JP7706169B2 (ja) * | 2020-02-26 | 2025-07-11 | 上海科技大学 | 抗コロナウイルスにおけるジスルフィラムの使用 |
| CN114507215B (zh) * | 2020-11-14 | 2024-09-13 | 成都海博为药业有限公司 | 一种作为pak4激酶抑制剂的化合物及其制备方法和应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| DE19818044A1 (de) | 1998-04-22 | 1999-10-28 | Klinge Co Chem Pharm Fab | Verwendung von Vitamin-PP-Verbindungen |
| JP2004534857A (ja) | 2001-07-19 | 2004-11-18 | フアルマシア・イタリア・エツセ・ピー・アー | フェニルアセトアミド−チアゾール誘導体、それらの製造のための方法及び抗癌剤としてのそれらの使用 |
| EP1348434A1 (en) | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
| US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| US7078419B2 (en) | 2003-03-10 | 2006-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
| WO2004106317A1 (ja) | 2003-05-29 | 2004-12-09 | The New Industry Research Organization | ベンゾフラン化合物、およびそれを含有してなる医薬組成物 |
| JP4709757B2 (ja) | 2003-08-07 | 2011-06-22 | ニツポネツクス・インコーポレーテツド | 過剰増殖性障害の処置に有用なベンゾフラン誘導体 |
| US7368476B2 (en) | 2004-04-07 | 2008-05-06 | Pharmacyclics, Inc. | Hydroxamates as therapeutic agents |
| EP2261218B1 (en) | 2004-05-26 | 2013-04-03 | Eisai R&D Management Co., Ltd. | Imidazole compound for use as an intermediate in the production of cinnamide compounds |
| WO2006038606A1 (ja) | 2004-10-05 | 2006-04-13 | Shionogi & Co., Ltd. | ビアリール誘導体 |
| US8084492B2 (en) | 2004-11-19 | 2011-12-27 | The New Industry Research Organization | Benzofuran compound and pharmaceutical composition containing the same |
| BRPI0608659A2 (pt) | 2005-04-06 | 2010-11-30 | Astrazeneca Ab | composto, métodos para limitar a proliferação celular, de tratamento de um ser humano ou animal sofrendo de uma doença, e de tratamento de profilaxia do cáncer, para tratar cáncer, de tratamento de infecções associadas com cáncer, e de profilaxia de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir chk1 cinase, e um pak cinase, e para limitar a tumorigênese em um ser humano ou animal, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo |
| JP2008538571A (ja) | 2005-04-22 | 2008-10-30 | ワイス | ジヒドロベンゾフラン誘導体およびその使用 |
| US20080020413A1 (en) | 2006-03-29 | 2008-01-24 | Columbia University | Crystalline visfatin and methods therefor |
| WO2008026018A1 (en) | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
| EP2003118A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Zimtsäurederivate als Modulatoren des EP2-Rezeptors |
| EP2197443A4 (en) | 2007-09-26 | 2014-01-01 | Gemin X Pharmaceuticals Canada Inc | COMPOSITIONS AND METHOD FOR LEADING NAD + MIRRORS USING A NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE HEMMER |
| US8173677B2 (en) | 2007-09-26 | 2012-05-08 | Gemin X Pharmaceuticals Canada Inc. | Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
| EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| FR2943669B1 (fr) | 2009-03-24 | 2011-05-06 | Sanofi Aventis | Derives de nicotinamide,leur preparation et leur application en therapeutique |
| US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
| BR112012021806A2 (pt) | 2010-03-01 | 2015-09-08 | Myrexis Inc | compostos e seus usos terapêusticos. |
| US20130317027A1 (en) | 2010-03-01 | 2013-11-28 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| JP5978293B2 (ja) | 2011-05-04 | 2016-08-24 | フォーマ ティーエム, エルエルシー. | Namptを阻害するための新規な化合物および組成物 |
| EP2739144A4 (en) | 2011-06-20 | 2015-04-01 | Alzheimer S Inst Of America Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
| WO2013082150A1 (en) | 2011-11-30 | 2013-06-06 | The Curators Of The University Of Missouri | Small molecule inhibitors of nicotinamide phosphoribosyltransferase (nampt) |
| WO2014074715A1 (en) | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Cyclopropyl amide derivatives |
| EP2925750A1 (en) * | 2012-11-29 | 2015-10-07 | Karyopharm Therapeutics, Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
| WO2014111871A1 (en) | 2013-01-17 | 2014-07-24 | Aurigene Discovery Technologies Limited | 4,5-dihydroisoxazole derivatives as nampt inhibitors |
| JP6397010B2 (ja) * | 2013-07-03 | 2018-09-26 | カリオファーム セラピューティクス,インコーポレイテッド | 置換されたベンゾフラニル及びベンゾオキサゾリル化合物並びにその使用 |
| WO2015042414A1 (en) | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
| WO2015054060A1 (en) | 2013-10-09 | 2015-04-16 | Eli Lilly And Company | Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors |
| WO2016100515A1 (en) | 2014-12-16 | 2016-06-23 | Karyopharm Therapeutics Inc. | Cyclic compounds and uses thereof |
| WO2017031213A1 (en) | 2015-08-17 | 2017-02-23 | Karyopharm Therapeutics Inc. | 3-(pyridin-3-yl)-acrylamide and n-(pyridin-3-yl)-acrylamide derivatives and their use as pak or nampt modulators |
| WO2017031204A1 (en) | 2015-08-17 | 2017-02-23 | Karyopharm Therapeutics Inc. | Cyclopropylderivatives and their use as kinase inhibitors |
| WO2017031323A1 (en) | 2015-08-18 | 2017-02-23 | Karyopharm Therapeutics Inc. | (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer |
| US10858347B2 (en) | 2015-12-31 | 2020-12-08 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
| US20190002448A1 (en) | 2015-12-31 | 2019-01-03 | Karyopharm Therapeutics Inc. | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof |
-
2016
- 2016-08-18 WO PCT/US2016/047566 patent/WO2017031323A1/en not_active Ceased
- 2016-08-18 HK HK18114602.1A patent/HK1255438A1/zh unknown
- 2016-08-18 MX MX2018001979A patent/MX2018001979A/es unknown
- 2016-08-18 EA EA201890524A patent/EA201890524A1/ru unknown
- 2016-08-18 AU AU2016308829A patent/AU2016308829A1/en not_active Abandoned
- 2016-08-18 CN CN201680060621.6A patent/CN108137563A/zh active Pending
- 2016-08-18 US US15/753,897 patent/US10363247B2/en active Active
- 2016-08-18 JP JP2018509622A patent/JP2018528196A/ja active Pending
- 2016-08-18 CA CA2995380A patent/CA2995380A1/en not_active Abandoned
- 2016-08-18 EP EP16756931.8A patent/EP3337797A1/en not_active Withdrawn
- 2016-08-18 MA MA042655A patent/MA42655A/fr unknown
-
2018
- 2018-02-08 IL IL257422A patent/IL257422A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016308829A1 (en) | 2018-03-08 |
| MX2018001979A (es) | 2019-04-25 |
| JP2018528196A (ja) | 2018-09-27 |
| EA201890524A1 (ru) | 2018-07-31 |
| US10363247B2 (en) | 2019-07-30 |
| CN108137563A (zh) | 2018-06-08 |
| WO2017031323A1 (en) | 2017-02-23 |
| MA42655A (fr) | 2021-04-07 |
| US20180235948A1 (en) | 2018-08-23 |
| IL257422A (en) | 2018-04-30 |
| HK1255438A1 (zh) | 2019-08-16 |
| EP3337797A1 (en) | 2018-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11746102B2 (en) | Polymorphs of selinexor | |
| US20260085064A1 (en) | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | |
| US10526295B2 (en) | Nuclear transport modulators and uses thereof | |
| US10363247B2 (en) | (S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer | |
| US20160016916A1 (en) | Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof | |
| US10709706B2 (en) | Nuclear transport modulators and uses thereof | |
| US10858347B2 (en) | Multicyclic compounds and uses thereof | |
| WO2014205393A1 (en) | Nuclear transport modulators and uses thereof | |
| US20180244660A1 (en) | Cyclopropylderivatives and their use as kinase inhibitors | |
| US20190218207A1 (en) | 3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT Modulators | |
| US9994558B2 (en) | Multicyclic compounds and methods of using same | |
| US20170369470A1 (en) | Cyclic Compounds and Uses Thereof | |
| US20190002448A1 (en) | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | |
| HK1223937B (en) | Substituted benzofuranyl and benzoxazolyl compounds and pharmaceutical uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220301 |